Jardiance for Weight Loss

Jardiance is sometimes mentioned for weight loss — but it’s a different kind of drug from the GLP-1s. Here’s how much it actually does, and how it compares to medications built for weight loss.

The short answer

Jardiance (empagliflozin) is an SGLT2 diabetes drug — not a GLP-1 — and causes only modest weight loss (~2%, 4–7 lb) as a side effect. GLP-1s produce 3–4× more (semaglutide ~15%, tirzepatide ~21%). For weight loss specifically, a GLP-1 is far more effective.

Jardiance vs GLP-1 weight-loss efficacy
Medication	Avg. weight loss	Class
Jardiance (empagliflozin)	~2% (4–7 lb)	SGLT2 inhibitor
Semaglutide (Wegovy)	~15%	GLP-1
Tirzepatide (Zepbound)	~21%	GLP-1 + GIP

Does Jardiance work for weight loss?

Only modestly. By making you pass glucose in urine, Jardiance leads to about 2% body-weight loss — a side effect, not its purpose. It’s an important diabetes, heart, and kidney drug, but not a weight-loss treatment.

Why GLP-1 is far more effective — and how to get it

GLP-1 medications act on appetite and produce several times Jardiance’s weight loss. Compare them in best GLP-1 for weight loss, and get one through a licensed telehealth provider if appropriate — see below.

For real weight loss, compare GLP-1 options

Common questions about Jardiance for weight loss

Does Jardiance cause weight loss?

A little. Jardiance (empagliflozin) is an SGLT2 inhibitor for type 2 diabetes that makes you excrete glucose in urine, leading to modest weight loss — about 2% of body weight (roughly 4–7 lb). It’s not a weight-loss medication, and the effect is small compared with GLP-1s.

Is Jardiance or Ozempic better for weight loss?

For weight loss, GLP-1s win clearly. Jardiance averages ~2% body weight, while semaglutide (Ozempic/Wegovy) averages ~15% and tirzepatide ~21% — about 3–4× more. Jardiance has important heart and kidney benefits in diabetes, but it isn’t a weight-loss drug.

Is Jardiance a GLP-1?

No. Jardiance is an SGLT2 inhibitor, a different drug class from GLP-1 medications. They work by completely different mechanisms; GLP-1s act on appetite and produce far greater weight loss.

Sources & freshness

Reflects empagliflozin weight data (~2% / 4–7 lb, SGLT2 class) vs GLP-1s (semaglutide ~15%, tirzepatide ~21%). Verified 2026-06-30. Educational only, not medical advice.

Medication

Avg. weight loss

Class

Jardiance (empagliflozin)

~2% (4–7 lb)

SGLT2 inhibitor

Semaglutide (Wegovy)

~15%

GLP-1

Tirzepatide (Zepbound)

~21%

GLP-1 + GIP